Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up After Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares gapped up before the market opened on Wednesday after Guggenheim raised their price target on the stock from $46.00 to $58.00. The stock had previously closed at $44.18, but opened at $46.59. Guggenheim currently has a buy rating on the stock. Maze Therapeutics shares last traded at $45.24, with a volume of 35,021 shares.

A number of other equities analysts also recently commented on the company. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company started coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective on the stock. Wedbush raised their price objective on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, BTIG Research boosted their target price on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.57.

Insiders Place Their Bets

In other news, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. The trade was a 27.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 200,000 shares of company stock valued at $8,254,792.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MAZE. Frazier Life Sciences Management L.P. grew its stake in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its position in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after acquiring an additional 362,060 shares during the last quarter. Woodline Partners LP grew its position in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Maze Therapeutics by 9.0% in the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after purchasing an additional 69,771 shares during the last quarter.

Maze Therapeutics Stock Performance

The stock has a market cap of $2.18 billion, a PE ratio of -2.17 and a beta of 4.47. The firm’s 50-day moving average is $43.85 and its 200 day moving average is $34.11.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.